SU5416 (Semaxanib): Selective VEGFR2 Tyrosine Kinase Inhibitor for Angiogenesis and Immune Modulation Research

Executive Summary: SU5416 (Semaxanib) is a small molecule inhibitor with high selectivity for the VEGFR2/Flk-1/KDR tyrosine kinase, blocking VEGF-induced endothelial proliferation and angiogenesis (Neelakantan et al., 2025). It demonstrates potent anti-tumor effects in vivo, with IC₅₀ values in the sub-micromolar range for HUVEC mitogenesis (APExBIO). Beyond angiogenesis, SU5416 also acts as an AHR agonist, facilitating immune regulation through IDO induction and Treg differentiation (Related Article). The compound's solubility profile (≥11.9 mg/mL in DMSO) and stability at -20°C make it suitable for both in vitro and in vivo experimentation. APExBIO supplies SU5416 (SKU A3847) with validated purity and dosing guidelines for reproducible research outcomes.

Biological Rationale

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a critical process in both physiological tissue repair and pathological states such as cancer and pulmonary hypertension (Neelakantan et al., 2025). Vascular endothelial growth factor (VEGF) signaling via VEGFR2 (Flk-1/KDR) is the principal driver of endothelial cell proliferation and neovascularization. Overactivation of VEGFR2 correlates with tumor vascularization, metastatic potential, and poor prognosis across multiple cancers. Selective inhibition of VEGFR2 provides a targeted strategy to suppress pathological angiogenesis without the broader toxicity of pan-kinase inhibitors. In addition, modulation of immune responses via the aryl hydrocarbon receptor (AHR) pathway is emerging as a relevant mechanism in tumor microenvironment regulation and autoimmunity. SU5416 (Semaxanib) addresses both of these axes by inhibiting VEGFR2-driven angiogenesis and functioning as an AHR agonist.

Mechanism of Action of SU5416 (Semaxanib) VEGFR2 inhibitor

SU5416 is a highly selective small molecule that binds to the ATP-binding site of VEGFR2 (Flk-1/KDR) receptor tyrosine kinase, effectively blocking VEGF-induced phosphorylation and subsequent activation of downstream signaling pathways. This blockade leads to the inhibition of endothelial cell proliferation, migration, and tube formation—hallmarks of angiogenesis. In addition, SU5416 acts as an agonist of the AHR, a ligand-activated transcription factor involved in immune modulation. Activation of AHR by SU5416 induces expression of indoleamine 2,3-dioxygenase (IDO), promoting the differentiation of regulatory T cells (Tregs) and altering local immune responses. The compound exhibits its biological activities at concentrations ranging from 0.01–100 μM in vitro, with an IC₅₀ of 0.04 ± 0.02 μM for VEGF-driven HUVEC mitogenesis inhibition (APExBIO). In vivo, SU5416 suppresses tumor growth in mouse xenograft models at daily doses of 1–25 mg/kg via intraperitoneal injection.

Evidence & Benchmarks

• SU5416 inhibits VEGFR2-mediated endothelial cell proliferation with an IC₅₀ of 0.04 ± 0.02 μM in HUVEC cells (APExBIO datasheet).
• In mouse xenograft models, daily intraperitoneal administration of SU5416 at 1–25 mg/kg significantly reduces tumor growth without observed mortality at higher doses (Related Article).
• SU5416 is insoluble in ethanol and water but achieves ≥11.9 mg/mL solubility in DMSO, enabling consistent dosing for in vitro and in vivo studies (APExBIO).
• As an AHR agonist, SU5416 induces IDO expression and Treg differentiation, expanding its relevance to immune modulation and autoimmune research (Related Article).
• VEGF-VEGFR2 axis modulation is critical in diseases involving vascular remodeling, such as pulmonary hypertension, where pathological angiogenesis contributes to increased vascular resistance and right ventricular afterload (Neelakantan et al., 2025).

For additional quantitative and scenario-driven insights, see "Enhancing Angiogenesis Assays with SU5416 (Semaxanib) VEGFR2 inhibitor", which details practical assay optimization; this article updates those findings by integrating new data on immune modulation and dosing precision.

Applications, Limits & Misconceptions

SU5416 (Semaxanib) is primarily used in preclinical research to:

• Suppress VEGF-driven angiogenesis in cancer models.
• Study tumor vascularization and metastasis suppression.
• Investigate mechanisms of immune modulation (AHR agonism, IDO induction, Treg differentiation).
• Model pulmonary hypertension via induced vascular remodeling (Neelakantan et al., 2025).

For a mechanistic deep-dive, "SU5416 (Semaxanib): Selective VEGFR2 Tyrosine Kinase Inhibitor" focuses on angiogenesis suppression; this dossier extends scope to immune and workflow dimensions.

Common Pitfalls or Misconceptions

• SU5416 is not effective in models where angiogenesis is not VEGF/VEGFR2-dependent.
• Its lack of solubility in water and ethanol requires careful preparation in DMSO; improper solubilization can compromise bioavailability (APExBIO).
• Clinical translation is limited; SU5416 is not approved for human therapeutic use and is restricted to research applications only.
• The immune modulatory effects via AHR are context-dependent and may not generalize across all autoimmune or transplant models.
• High doses in non-target species or without proper formulation can lead to off-target toxicity.

See "SU5416 (Semaxanib): Selective VEGFR2 Inhibitor for Tumor Angiogenesis" for a summary of efficacy boundaries; this article corrects key misconceptions regarding immune selectivity.

Workflow Integration & Parameters

For experimental use, SU5416 (SKU A3847) is best prepared as a stock solution in DMSO (≥11.9 mg/mL), optionally warmed to 37°C or sonicated to enhance dissolution. Stocks remain stable for several months at -20°C. Working concentrations for in vitro studies typically range from 0.01–100 μM, with optimal efficacy observed at 0.04 μM for VEGF-driven assays. For in vivo xenograft models, daily intraperitoneal administration at 1–25 mg/kg is recommended, balancing efficacy and safety. APExBIO provides validated protocols and purity documentation to support reproducibility (official product page). For troubleshooting and Q&A on workflow performance, refer to "Scenario-Driven Solutions with SU5416 (Semaxanib) VEGFR2 inhibitor", which this article extends by providing updated solubility and immune modulation data.

Conclusion & Outlook

SU5416 (Semaxanib) is a validated, highly selective VEGFR2 inhibitor with robust anti-angiogenic and immune modulatory properties. Its dual mechanism—VEGFR2 blockade and AHR agonism—enables broad applicability in cancer, angiogenesis, and immunology research. APExBIO (SKU A3847) supplies high-purity SU5416 with detailed use guidelines, supporting reproducibility and translational insight. Future research may further delineate its role in vascular remodeling and immune regulation in disease models. For comprehensive technical details and ordering, visit the SU5416 (Semaxanib) VEGFR2 inhibitor product page.